Skip to main content
SpringerLink
Log in

Radionuclide Imaging of Gastrointestinal Neuroendocrine Tumors

  • Chapter
  • First Online:
Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Part of the book series: Contemporary Endocrinology ((COE))

  • 1164 Accesses

Abstract

Neuroendocrine tumors (NETs) are rare and heterogeneous epithelial neoplasms with neuroendocrine differentiation commonly originating from the gastrointestinal tract. In the evaluation of patients with suspected or known NETs, a multidisciplinary strategy including both radiological studies and nuclear medicine examinations is usually proposed to provide optimal therapeutic management. This chapter will focus on medical imaging for gastrointestinal NETs with emphasis on nuclear medicine techniques, taking into account the patient clinical context and both strengths and limitations of each diagnostic modality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder W, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424.

    Article  CAS  PubMed  Google Scholar 

  2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  3. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.

    Article  PubMed  Google Scholar 

  4. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691–703.

    Article  CAS  PubMed  Google Scholar 

  5. Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186–92.

    Article  CAS  PubMed  Google Scholar 

  6. Klöppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010;456:595–7.

    Article  PubMed  Google Scholar 

  7. La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938–48.

    Article  PubMed  Google Scholar 

  8. Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, Thomas D, Tsolakis AV, Gross D, et al. Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2014;81:157–68.

    Article  Google Scholar 

  9. Dobson R, Burgess MI, Pritchard DM, Cuthbertson DJ. The clinical presentation and management of carcinoid heart disease. Int J Cardiol. 2014;173:29–32.

    Article  CAS  PubMed  Google Scholar 

  10. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26:791–802.

    Article  CAS  PubMed  Google Scholar 

  11. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458–511.

    Article  CAS  PubMed  Google Scholar 

  12. Landry CS, Scoggins CR, McMasters KM, Martin 2nd RC. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97:253–8.

    Article  PubMed  Google Scholar 

  13. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17:49–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bellutti M, Fry LC, Schmitt J, Seemann M, Klose S, Malfetheiner P, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009;54:1050–8.

    Article  PubMed  Google Scholar 

  15. Yamagishi H, Fukui H, Shirakawa K, Oinuma T, Hirashi H, Terano A, et al. Early diagnosis and successful treatment of small-intestinal carcinoid tumor: useful combination of capsule endoscopy and double-balloon endoscopy. Endoscopy. 2007;39 Suppl 1:E243–4.

    Article  PubMed  Google Scholar 

  16. Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small bowel capsule endoscopy: a systematic review. Gastrointest Endosc. 2010;71:280–6.

    Article  PubMed  Google Scholar 

  17. Modlin IM, Gustafsson BI, Kidd M. Gastrointestinal carcinoid tumours. In: Howden CW, editor. Advances in digestive disease. Bethesda: AGA Institute Press; 2007.

    Google Scholar 

  18. Patel KK, Kim MK. Neuroendocrine tumors of the pancreas: endoscopic diagnosis. Curr Opin Gastroenterol. 2008;24:638–42.

    Article  PubMed  Google Scholar 

  19. Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Neuroendocrine tumors of the small bowels are on the rise: early aspects and management. World J Gastrointest Endosc. 2010;2:325–34.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Binstock AJ, Johnson CD, Stephens DH, Lloyd RV, Fletcher JG. Carcinoid tumors of the stomach: a clinical and radiographic study. AJR Am J Roentgenol. 2001;176:947–51.

    Article  CAS  PubMed  Google Scholar 

  21. Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr. 1995;19:400–5.

    Article  CAS  PubMed  Google Scholar 

  22. Kamaoui I, De-Luca V, Ficarelli S, Mennesson N, Lombard-Bohas C, Pilleul F. Value of CT enteroclysis in suspected small-bowel carcinoid tumors. AJR Am J Roentgenol. 2010;194:629–33.

    Article  PubMed  Google Scholar 

  23. Masselli G, Polettini E, Casciani E, Bertini L, Vecchioli A, Gualdi G. Small-bowel neoplasms: prospective evaluation of MR enteroclysis. Radiology. 2009;251:743–50.

    Article  PubMed  Google Scholar 

  24. Van Weyenberg SJ, Meijerink MR, Jacobs MA, Van der Peet DL, Van Kuijk C, Mulder CJ, et al. MR enteroclysis in the diagnosis of small-bowel neoplasms. Radiology. 2010;254:765–73.

    Article  PubMed  Google Scholar 

  25. Pantongrag-Brown L, Buetow PC, Carr NJ, Lichtenstein JE, Buck JL. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am J Roentgenol. 1995;164:387–91.

    Article  CAS  PubMed  Google Scholar 

  26. Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251:307–10.

    Article  PubMed  Google Scholar 

  27. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998;206:143–50.

    Article  CAS  PubMed  Google Scholar 

  28. Elsayes KM, Menias CO, Bowerson M, Osman OM, Alkharouby AM, Hillen TJ. Imaging of carcinoid tumors: spectrum of findings with pathologic and clinical correlation. J Comput Assist Tomogr. 2011;35:72–80.

    Article  PubMed  Google Scholar 

  29. Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol. 2003;180:121–8.

    Article  PubMed  Google Scholar 

  30. Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216:163–71.

    Article  CAS  PubMed  Google Scholar 

  31. Koh DM, Brown G, Riddell AM, Scurr E, Collins DJ, Allen SD, et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol. 2008;18:903–10.

    Article  CAS  PubMed  Google Scholar 

  32. Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008;190:67–73.

    Article  PubMed  Google Scholar 

  33. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol. 1998;16:1040–53.

    CAS  PubMed  Google Scholar 

  34. Scarsbrook AF, Ganeshan A, Statham J, Thakker RV, Weaver A, Talbot D, et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics. 2007;27:455–77.

    Article  PubMed  Google Scholar 

  35. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003;44:184–91.

    PubMed  Google Scholar 

  36. Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999–1017.

    Article  CAS  PubMed  Google Scholar 

  37. Kaemmerer D, Peter L, Lupp A, et al. Molecular imaging with (6)(8)Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:1659–68.

    Article  CAS  PubMed  Google Scholar 

  38. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4.

    Article  CAS  PubMed  Google Scholar 

  39. Arnold R, Chen YJ, Costa F, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.

    Article  CAS  PubMed  Google Scholar 

  40. Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–12.

    Article  PubMed  Google Scholar 

  41. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  42. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

    Article  PubMed  CAS  Google Scholar 

  43. FROM ECC 2015-neuroendocrine cancer: SSA therapies-(177)Lu-DOTATATE is a better one in NETTER-1. Nat Rev Clin Oncol 2015;12:684

    Google Scholar 

  44. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.

    Article  CAS  PubMed  Google Scholar 

  45. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.

    Article  CAS  PubMed  Google Scholar 

  46. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.

    Article  CAS  PubMed  Google Scholar 

  47. Van Binnebeek S, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumors. Eur Radiol. 2016;26:900–9.

    Article  PubMed  Google Scholar 

  48. Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34:588–96.

    Article  CAS  PubMed  Google Scholar 

  49. Morgat C, Vélayoudom-Céphise FL, Schwartz P, et al. Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016;28:1258–66.

    Google Scholar 

  50. Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259–77.

    Article  CAS  PubMed  Google Scholar 

  51. Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864–70.

    Article  CAS  PubMed  Google Scholar 

  52. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.

    Article  PubMed  Google Scholar 

  53. Bombardieri E, Ambrosini V, Aktolun C, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.

    Article  PubMed  Google Scholar 

  54. Naswa N, Sharma P, Kumar A, et al. (6)(8)Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med. 2012;37:245–51.

    Article  PubMed  Google Scholar 

  55. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412–7.

    Article  CAS  PubMed  Google Scholar 

  57. Pfeifer A, Knigge U, Binderup T, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847–54.

    Article  CAS  PubMed  Google Scholar 

  58. Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010;51:454–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Gornik G, Weber W. New tracers beyond FDG in head and neck oncology. Q J Nucl Med Mol Imaging. 2011;55:529–40.

    CAS  PubMed  Google Scholar 

  60. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915–8.

    Article  CAS  PubMed  Google Scholar 

  61. Santhanam P, Taïeb D. Role of (18)F-FDOPA PET/CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81:789–98.

    Article  CAS  Google Scholar 

  62. Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, et al. Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging. 2011;38:1854–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–86.

    Article  CAS  PubMed  Google Scholar 

  64. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med. 2004;45:1161–7.

    CAS  PubMed  Google Scholar 

  65. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Välimäki M, Nuutila P. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16:255–65.

    Article  CAS  PubMed  Google Scholar 

  66. Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology. 2015;101:1–17.

    Article  CAS  PubMed  Google Scholar 

  67. Montravers F, Kerrou K, Nataf V, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94:1295–301.

    Article  CAS  PubMed  Google Scholar 

  68. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumours? J Nucl Med. 2006;47:1455–62.

    CAS  PubMed  Google Scholar 

  69. Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 2008;68:7183–90.

    Article  CAS  PubMed  Google Scholar 

  70. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with 18FDOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728–34.

    Article  CAS  PubMed  Google Scholar 

  71. Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, et al. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med. 2014;55:367–72.

    Article  CAS  PubMed  Google Scholar 

  72. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–80.

    Article  CAS  PubMed  Google Scholar 

  73. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604–9.

    Article  CAS  PubMed  Google Scholar 

  74. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–31.

    Article  CAS  PubMed  Google Scholar 

  75. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.

    Article  CAS  PubMed  Google Scholar 

  76. Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765–70.

    Article  CAS  PubMed  Google Scholar 

  77. Modlin IM, Gustafsson BI, Kidd M. Gastrointestinal carcinoid tumors. In: Howden CW, Baillie J, Buchman AL, Metz DC, Modlin IM, editors. Advances in digestive disease. Bethesda: AGA Institute Press; 2007. p. 203–18.

    Google Scholar 

  78. Jaenigen B, Kayser G, Steinke B, Thomusch O. Five-year long-term follow-up of a primary lymph node gastrinoma: is a pancreaticoduodenectomy justified? Case Rep Med. 2009;2009:762–91.

    Google Scholar 

  79. Rothenstein J, Clearly SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract. A decade of experience at the Princess Margaret Hospital. Am J Clin Oncol. 2008;31:64–70.

    Article  PubMed  Google Scholar 

  80. Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Tiensuu Janson E, Akerström G. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991–7.

    Article  PubMed  Google Scholar 

  81. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  83. Butkr AP, Thomas RM, Elsayed AM, Sobin HL. Carcinoids of the jejunum and ileum. Cancer. 1997;79:1086–93.

    Article  Google Scholar 

  84. Pasquier A, Walter T, Hervieu V, Forestier J, Scoazec JY, Lombard-Bohas C, et al. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;22 suppl 3:742–9.

    Article  Google Scholar 

  85. Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40:943–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Imperiale A, Averous G, Chilinseva-Natorov N, Hubelé F, Triki E, Bellocq JP, et al. Unknown multifocal ileal carcinoid revealed by (18)F-FDOPA PET/CT. J Clin Endocrinol Metab. 2014;99:1510–1.

    Article  CAS  PubMed  Google Scholar 

  87. Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, et al. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2014;99:63–74.

    Article  CAS  PubMed  Google Scholar 

  88. Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, et al. Performance of 18Fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki-67 (>=10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96:665–71.

    Google Scholar 

  89. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med. 1991;32:623–48.

    CAS  PubMed  Google Scholar 

  90. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83.

    Article  CAS  PubMed  Google Scholar 

  91. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727–34.

    Article  CAS  PubMed  Google Scholar 

  92. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010;10 Spec no A:S83-91.

    Google Scholar 

  93. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858–64.

    Article  CAS  PubMed  Google Scholar 

  94. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.

    Article  CAS  PubMed  Google Scholar 

  95. Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786–90.

    Article  CAS  PubMed  Google Scholar 

  96. Ezziddin S, Adler L, Sabet A, Pöppel AD, Grabellus F, Yüce A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260–6.

    Article  CAS  PubMed  Google Scholar 

  97. Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881–8.

    Article  CAS  PubMed  Google Scholar 

  98. Fuccio C, Musto A, Cambioli S, Castellucci P, Pantaleo MA, Nanni C, et al. When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors? Clin Nucl Med. 2011;36:1109–11.

    Article  PubMed  Google Scholar 

  99. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med. 2005;46 Suppl 1:76S–82.

    PubMed  Google Scholar 

  100. Van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol. 2014;10:102–14.

    Article  PubMed  CAS  Google Scholar 

  101. Cerci JJ, Pereira Neto CC, Krauzer C, Sakamoto DG, Vitola JV, et al. The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2013;40:98–103.

    Article  PubMed  Google Scholar 

  102. Shyn PB. Interventional positron emission tomography/computed tomography: state-of-the-art. Tech Vasc Interv Radiol. 2013;16:182–90.

    Article  PubMed  Google Scholar 

  103. Bonichon F, Godbert Y, Buy X, Palussière J. PET/computed tomography and thermoablation (radiofrequency, microwave, cryotherapy, laser interstitial thermal therapy). PET Clin. 2015;10:519–40.

    Article  PubMed  Google Scholar 

  104. Imperiale A, Garnon J, Bachellier P, Gangi A, Namer IJ. Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach. Clin Nucl Med. 2015;40:e334–5.

    Article  PubMed  Google Scholar 

  105. European Society of Radiology (ESR). Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging. 2015;6:141–55.

    Article  Google Scholar 

  106. Bouchelouche K, Capala J. ‘Image and treat’: an individualized approach to urological tumors. Curr Opin Oncol. 2010;22:274–80.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biophysics and Nuclear Medicine Department, Hautepierre Hospital, University Hospitals of Strasbourg, 1, Avenue Molière, 67098, Strasbourg, Cedex 09, France

    Alessio Imperiale MD, PhD

  2. ICube, University of Strasbourg, Strasbourg, France

    Alessio Imperiale MD, PhD

  3. Nuclear Medicine, University Hospitals Leuven, and Department of Imaging & Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium

    Christophe M. Deroose MD, PhD

  4. Nuclear Medicine Department, Haut-Lévêque Hospital, CHU Bordeaux, University of Bordeaux, Avenue Magellan, 33604, Pessac, France

    Elif Hindié MD, PhD

  5. LabEx TRAIL, University of Bordeaux, Bordeaux, France

    Elif Hindié MD, PhD

  6. Internal Medicine Department, Hautepierre Hospital, University Hospitals of Strasbourg, 1, Avenue Molière, 67098, Strasbourg, Cedex 09, France

    Bernard Goichot MD, PhD

Authors
  1. Alessio Imperiale MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe M. Deroose MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elif Hindié MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernard Goichot MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessio Imperiale MD, PhD .

Editor information

Editors and Affiliations

  1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland, USA

    Karel Pacak

  2. Department of Nuclear Medicine, Aix-Marseille University, Marseille, France

    David Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Imperiale, A., Deroose, C.M., Hindié, E., Goichot, B. (2017). Radionuclide Imaging of Gastrointestinal Neuroendocrine Tumors. In: Pacak, K., Taïeb, D. (eds) Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-46038-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46038-3_15

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-46036-9

  • Online ISBN: 978-3-319-46038-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation